Literature DB >> 25464438

Passive transfer of affinity-purified anti-heart autoantibodies (AHA) from sera of patients with myocarditis induces experimental myocarditis in mice.

Alida L P Caforio1, Annalisa Angelini2, Miri Blank3, Alice Shani3, Shaye Kivity3, Gisele Goddard4, Andrea Doria5, Alessandro Schiavo6, Martina Testolina6, Stefania Bottaro7, Renzo Marcolongo8, Gaetano Thiene2, Sabino Iliceto6, Yehuda Shoenfeld9.   

Abstract

BACKGROUND: Human autoimmune myocarditis is characterized by an increased frequency of serum organ and disease-specific anti-heart autoantibodies (AHA) in affected patients. To assess whether AHA are directly pathogenic, we used the passive transfer technique of AHA from patients to normal Balb/c mice to induce an experimental myocarditis.
METHODS: In keeping with a classical passive transfer experiment, sera from 5 AHA positive myocarditis patients (3 male, mean age 30 ± 11 years, 3 with giant cell and 2 with lymphocytic myocarditis) were affinity purified and injected into 25 Balb/c mice. As controls, affinity purified sera from 5 healthy donors were passively transferred to 25 Balb/c mice. Further 15 control mice were injected with phosphate-buffered saline and 9 mice did not receive any injection. In all patients cardiac-specific AHA of IgG class had been previously detected by an indirect immunofluorescence (IFL) technique on cryostat sections of O blood group human heart. The animals were sacrificed after 4 weeks and the hearts were blindly examined for histological evidence of myocarditis by an expert cardiac pathologist.
RESULTS: Myocarditis was present in 13/25 (52%) of the mice which received affinity-purified IgG from patients. The findings of severe, moderate or mild myocarditis were more common in the mice which received affinity-purified IgG from patients (20%; 20% and 12%) than in control animals (2%, p=0.01; 0%, p=0.003; and 0%, p=0.04 respectively).
CONCLUSIONS: These findings provide a new evidence for AHA-mediated pathogenicity in human myocarditis, according to Rose-Witebsky criteria.
Copyright © 2014 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Keywords:  Antibody; Immune system; Immunology; Myocarditis; Myosin

Mesh:

Substances:

Year:  2014        PMID: 25464438     DOI: 10.1016/j.ijcard.2014.10.165

Source DB:  PubMed          Journal:  Int J Cardiol        ISSN: 0167-5273            Impact factor:   4.164


  10 in total

Review 1.  Viral myocarditis.

Authors:  Noel R Rose
Journal:  Curr Opin Rheumatol       Date:  2016-07       Impact factor: 5.006

Review 2.  Pediatric Myocarditis: What Have We Learnt So Far?

Authors:  Elettra Pomiato; Marco Alfonso Perrone; Rosalinda Palmieri; Maria Giulia Gagliardi
Journal:  J Cardiovasc Dev Dis       Date:  2022-05-03

Review 3.  Roles of Host Immunity in Viral Myocarditis and Dilated Cardiomyopathy.

Authors:  Lifang Zhao; Zhaoying Fu
Journal:  J Immunol Res       Date:  2018-05-07       Impact factor: 4.818

4.  Population-based estimates of humoral autoimmunity from the U.S. National Health and Nutrition Examination Surveys, 1960-2014.

Authors:  Charles F Dillon; Michael H Weisman; Frederick W Miller
Journal:  PLoS One       Date:  2020-01-13       Impact factor: 3.240

Review 5.  Dilated cardiomyopathy.

Authors:  Heinz-Peter Schultheiss; DeLisa Fairweather; Alida L P Caforio; Felicitas Escher; Ray E Hershberger; Steven E Lipshultz; Peter P Liu; Akira Matsumori; Andrea Mazzanti; John McMurray; Silvia G Priori
Journal:  Nat Rev Dis Primers       Date:  2019-05-09       Impact factor: 65.038

Review 6.  Personalized Management of Myocarditis and Inflammatory Cardiomyopathy in Clinical Practice.

Authors:  Agata Tymińska; Krzysztof Ozierański; Aleksandra Skwarek; Agnieszka Kapłon-Cieślicka; Anna Baritussio; Marcin Grabowski; Renzo Marcolongo; Alida Lp Caforio
Journal:  J Pers Med       Date:  2022-01-30

7.  Heart non-specific effector CD4+ T cells protect from postinflammatory fibrosis and cardiac dysfunction in experimental autoimmune myocarditis.

Authors:  Martina Zarak-Crnkovic; Gabriela Kania; Agnieszka Jaźwa-Kusior; Marcin Czepiel; Winandus J Wijnen; Jarosław Czyż; Björn Müller-Edenborn; Daria Vdovenko; Diana Lindner; Cristina Gil-Cruz; Marta Bachmann; Dirk Westermann; Burkhard Ludewig; Oliver Distler; Thomas F Lüscher; Karin Klingel; Urs Eriksson; Przemysław Błyszczuk
Journal:  Basic Res Cardiol       Date:  2019-12-20       Impact factor: 17.165

8.  Prednisone and azathioprine in patients with inflammatory cardiomyopathy: systematic review and meta-analysis.

Authors:  Philippe Timmermans; Ana Barradas-Pires; Omar Ali; Michiel Henkens; Stephane Heymans; Kazuaki Negishi
Journal:  ESC Heart Fail       Date:  2020-07-27

Review 9.  Myocarditis and inflammatory cardiomyopathy: current evidence and future directions.

Authors:  Carsten Tschöpe; Enrico Ammirati; Biykem Bozkurt; Alida L P Caforio; Leslie T Cooper; Stephan B Felix; Joshua M Hare; Bettina Heidecker; Stephane Heymans; Norbert Hübner; Sebastian Kelle; Karin Klingel; Henrike Maatz; Abdul S Parwani; Frank Spillmann; Randall C Starling; Hiroyuki Tsutsui; Petar Seferovic; Sophie Van Linthout
Journal:  Nat Rev Cardiol       Date:  2020-10-12       Impact factor: 49.421

Review 10.  SARS-CoV-2 Myocarditis: Insights Into Incidence, Prognosis, and Therapeutic Implications.

Authors:  Ossama K Abou Hassan; Calvin C Sheng; Tom Kai Ming Wang; Paul C Cremer
Journal:  Curr Cardiol Rep       Date:  2021-08-03       Impact factor: 2.931

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.